CA2971024C — Fused ring heteroaryl compounds and their use as trk inhibitors
Assigned to CMG Pharmaceutical Co Ltd · Expires 2023-09-26 · 3y expired
What this patent protects
The disclosure provides novel chemical compounds represented by Formula (I) or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammatio…
USPTO Abstract
The disclosure provides novel chemical compounds represented by Formula (I) or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is -CH=CR3C(O)Nr4R5, -C=CC(O)NR4R5,-C= CC(0)NR4R5, or (II).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.